Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Sumitomo Dainippon Pharma Co ( (JP:4506) ) is now available.
Sumitomo Pharma has withdrawn its previously filed shelf registration in Japan for issuing new shares of common stock, following the completion of the planned equity offering under that framework. The withdrawal reflects that the company has already raised 41.58 billion yen through the shelf registration and separately sold additional shares worth 56.26 billion yen in overseas markets to institutional investors.
The end of this shelf registration program marks the conclusion of a significant capital-raising phase, which could strengthen the company’s financial base for future operations and investments. Sumitomo Pharma also notes that up to 7,695,600 additional shares may still be issued on May 26, 2026 via a third-party allotment tied to an over-allotment secondary offering, indicating continued fine-tuning of its equity structure.
The most recent analyst rating on (JP:4506) stock is a Buy with a Yen2700.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd., based in Osaka, Japan, is a pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange under securities code 4506. The company focuses on developing, manufacturing and selling prescription drugs, positioning itself as a key player in the Japanese and global healthcare markets.
YTD Price Performance: -11.09%
Average Trading Volume: 13,251,462
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen818.8B
Find detailed analytics on 4506 stock on TipRanks’ Stock Analysis page.